Can You Have Immunotherapy — With an Autoimmune Disease?

Usually yes, with closer monitoring — an autoimmune disease is not an automatic barrier to immunotherapy. Guidance from ASCO, ESMO and NCCN treats it as a risk to be assessed and managed, not as an absolute contraindication. The real questions are how active your condition is, what medicines control it, and who is monitoring you.

That is not what most people are told. Patients living with rheumatoid arthritis, psoriasis, thyroid disease, inflammatory bowel disease or lupus are often told informally that immunotherapy is “not for them” — sometimes at a reception desk, sometimes in a corridor, rarely after a formal assessment by the doctor who would actually prescribe it. A no reached that way is not a clinical decision. It is a guess made under time pressure.

There are situations where the caution is real and the answer may genuinely be no, or not yet. This page sets out which ones, what the flare risk actually looks like, and what a properly made decision involves — so you can tell the difference between an assessed no and an assumed one.

This page is general patient education. It cannot tell you whether immunotherapy is safe for you. That assessment needs your diagnosis, your disease activity, your current medicines and your scans in front of a medical oncologist working with the specialist who manages your autoimmune condition.

No. For most autoimmune conditions it is a caution, not a barrier. Patients with pre-existing autoimmune disease were largely excluded from the original registration trials, so the evidence comes from later published series and registries rather than randomised data. Current guidance still supports case-by-case consideration, with your autoimmune specialist involved from the start.

It helps to separate two different risks, because they get muddled constantly. The first is a flare of the condition you already have. The second is a new immune-related side effect in an organ your autoimmune disease has never touched — a thyroid, liver, bowel, lung or skin reaction that any patient on immunotherapy can develop. Having an autoimmune disease raises the first risk. It does not exempt you from the second.

Immunotherapy works by taking a brake off the immune system. If your immune system already attacks your own tissue, releasing that brake is a genuine consideration — which is exactly why the assessment exists, and why the monitoring plan for you looks different from the standard one.

The honest limitation is the evidence itself. Because these patients were excluded from the pivotal trials, precise numbers for any single condition do not exist. Anyone quoting you a confident percentage for your own disease is ahead of the data.

General patterns at guidance level only. Your own team’s assessment of your case overrides anything in this table, in either direction. If you have rheumatoid arthritis specifically, Immunotherapy With Rheumatoid Arthritis goes through that situation in more detail.

Real, and higher than for someone without an autoimmune condition — but usually manageable. Published series report flares in a substantial minority of patients. The figures vary too widely between series to quote one reliable number, and no honest source will give you a single percentage for your own disease.

Timing follows a rough pattern. Flares of an existing condition often appear in the first weeks to few months. New immune-related side effects can appear at any point, including after treatment finishes. Both are why your monitoring schedule is tighter than the standard one.

Management is usually familiar territory for both of your teams. In reported experience, most flares were handled by holding immunotherapy and using steroids or the condition’s own therapy, and a proportion of patients were able to resume treatment afterwards. Whether you resume is decided case by case by your oncologist with your specialist — it is not automatic, and it is not automatically ruled out either.

What makes the difference in practice is not the flare itself. It is how quickly it is recognised. A joint stiffness that you would normally sit out for a fortnight is worth reporting the same week when you are on immunotherapy, because the team needs to know whether it is your arthritis or something new.

Some symptoms should not wait for a scheduled review at all. New breathlessness or chest pain, severe or bloody diarrhoea, new double vision, drooping eyelids, difficulty swallowing or new muscle weakness, or yellowing of the eyes or skin: contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse. Do not manage these at home and do not wait for the next cycle. If you cannot reach your treating doctor, call 1800 202 8726.

Ask for the reason in writing, and ask which specialist was consulted. A properly reasoned no names your specific condition, your current medicines and what the alternative plan is. An unexplained no — given at a desk, or as a general rule about autoimmune patients — is worth a second opinion from a medical oncologist.

This is not about finding someone who will say yes. Sometimes a second opinion confirms the first answer, and that is a useful outcome too: you stop wondering, and you can put your energy into the treatment that is actually right for you. There are genuine reasons not to give immunotherapy, and Who Should Not Have Immunotherapy at All? goes through them without softening them.

What is not acceptable is a decision made without an assessment. Asking for one does not offend a treating team. Most oncologists would rather you asked than quietly accepted an answer nobody had actually worked out.

• Your current medicine list with doses — especially steroids, disease-modifying drugs and biologics. The dose matters as much as the name.
• Your autoimmune specialist’s most recent notes — the last consultation letter is usually enough to show how active the condition is.
• A short flare history — how often, how bad, what settled it, and when the last one was. Two lines is enough.
• Recent blood tests — including thyroid, liver and kidney function if you have them, so a baseline can be established quickly.
• Transplant details, if any — the organ, the year, the unit that follows you and your anti-rejection medicines. This changes the whole discussion.
• Your specialist’s contact details — so the two teams can speak directly rather than relaying messages through you.

• If you want the genuine contraindications set out honestly, Who Should Not Have Immunotherapy at All? covers who this treatment is not for.
• If a decision is close and you want to know which tests come first, Pre-Treatment Workup Before Starting Immunotherapy lists the baseline assessment.
• If your condition is rheumatoid arthritis specifically, Immunotherapy With Rheumatoid Arthritis goes deeper into that one situation.
• For how immunotherapy is delivered, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is safe, suitable or unsuitable for you — that assessment is made by your treating medical oncologist together with the specialist who manages your autoimmune condition. Response-assessment PET-CT is coordinated at partner imaging centres.

Get the Eligibility Question Answered Properly

A medical oncologist, working with the specialist who manages your autoimmune condition, can tell you where you actually stand — and what the monitoring plan would look like.

This page is general patient-education information, not a substitute for the written assessment your own oncology and autoimmune specialists give you for your specific case.